NEW YORK (GenomeWeb News) – PathoGenetix today announced it has secured $10 million in Series C financing to further commercialization efforts for its Genome Sequence Scanning technology.

Participants in the round included existing investors Ascension Health Ventures, Excel Venture Management, and HealthCare Ventures. The funding, PathoGenetix said, will be directed at further development of its first commercial system using the GSS technology, called the Resolution Microbial Genotyping System.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.